Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer.
作者信息
Corti C, Criscitiello C
机构信息
Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, Milan, Italy.
出版信息
ESMO Open. 2021 Apr;6(2):100063. doi: 10.1016/j.esmoop.2021.100063. Epub 2021 Mar 3.
Abstract
摘要
Zotero 插件